Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
about
Antibody therapies for lymphoma in childrenTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureNon-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges AheadMature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BLImmunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?International Pediatric Non-Hodgkin Lymphoma Response Criteria.Revised International Pediatric Non-Hodgkin Lymphoma Staging System.Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study ReportNovel approaches to pediatric leukemia treatment.Non-Hodgkin Lymphoma in Children.Emerging immunotherapy in pediatric lymphoma.Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic lNovel therapy for childhood acute lymphoblastic leukemia.Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013.Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.Pharmacotherapeutic Management of Pediatric Lymphoma.A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.Successful treatment of mature B-cell lymphoma with rituximab-based chemotherapy in a patient with Bloom syndrome.B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.Pediatric cryoglobulinemic vasculitis successfully managed with rituximab
P2860
Q24186437-D280A7C7-3066-4B7B-9D2B-8A7244F87B1CQ26746934-388FAA9E-34BC-4577-8491-803F0AD3B018Q26797513-28B9AC55-1567-4F4B-A0E5-AD2AF11A43A9Q30240133-A9FFEC72-D20B-4334-9E9F-97635CD87B03Q33709463-4C6A8D41-06B4-4BB4-BDAB-E24E7DD6CE5AQ35237511-FFEB248F-45AE-476B-A277-40423E8DE213Q35708769-E325F735-A456-49BE-BE84-2774172DF63FQ35708778-B0956D89-06C1-4575-A34B-79A5316EEC37Q35855211-A034F7EB-E9ED-4923-B6A6-8323557876B2Q38500371-78C07772-C0E2-4215-9265-F50262F8A749Q38547121-7D389940-E8C0-437C-AE46-66F8392CBBDDQ38652326-CF14AD19-D7AA-45FD-96E0-07C94A86FF33Q38687541-C7398A42-697C-480E-9F24-92AC307675DBQ38782141-71CFCEE2-399B-4E40-BB18-11BAA0987FF6Q38803361-3EA56DF3-EAEA-4FB3-9AD0-A6C1C58B6187Q38822525-DA920DC7-AA6B-41DF-878D-2E1C9C0871BCQ38827600-0709A3D5-4AE0-4C5B-A61F-11000211FD5FQ39368957-A3E8B66C-4587-42D7-84AA-3E2AA74F2D8CQ40411469-3F582028-CC0A-4D96-BFBD-58409FC991F2Q40695241-06B67812-5074-4346-9790-D65E1215AFE3Q47951320-489FC941-2A1E-4BB3-81BA-E94B153DD4E4Q48321203-5ACFFC86-090C-4A4F-B6E7-B0F1B9F67B2AQ49177202-E25B7DA4-0038-4756-8EA2-2D9F7655335CQ49789609-9543CF5C-ECE9-4469-848B-09281914E1D1Q51267093-B8B619A6-1545-4191-97BD-4EE6CCBE608DQ51441965-4AEDC5AF-08C5-4324-B280-8DDA74EEA9B6Q55010628-AEBCBF84-B00E-4954-89A9-CBA63845B13EQ58428977-F3D774EB-8903-46CD-9563-49137483C923
P2860
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@ast
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@en
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@nl
type
label
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@ast
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@en
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@nl
prefLabel
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@ast
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@en
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@nl
P2093
P2860
P921
P356
P1476
Rituximab with chemotherapy in ...... ldren's Oncology Group Report.
@en
P2093
Bruce Shiramizu
Howard Weinstein
James R Anderson
Lauren Harrison
Lynette Smith
Matthew Barth
Mitchell S Cairo
Paul Galardy
Sherrie L Perkins
Stanton Goldman
P2860
P304
P356
10.1111/BJH.13040
P407
P577
2014-07-26T00:00:00Z